Plus Price To Sales Ratio from 2010 to 2024
| PSTV Stock | USD 1.28 0.05 4.07% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 1.11879071 | Current Value 1.06 | Quarterly Volatility 18.43348665 |
Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 375.2 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.06, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
Plus | Price To Sales Ratio |
Latest Plus Therapeutics' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Plus Therapeutics over the last few years. Price to Sales Ratio is figured by comparing Plus Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Plus Therapeutics sales, a figure that is much harder to manipulate than other Plus Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Plus Therapeutics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 1.32 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Plus Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 14.97 | |
| Geometric Mean | 5.63 | |
| Coefficient Of Variation | 123.18 | |
| Mean Deviation | 14.25 | |
| Median | 6.73 | |
| Standard Deviation | 18.43 | |
| Sample Variance | 339.79 | |
| Range | 60.9431 | |
| R-Value | (0.19) | |
| Mean Square Error | 352.24 | |
| R-Squared | 0.04 | |
| Significance | 0.49 | |
| Slope | (0.80) | |
| Total Sum of Squares | 4,757 |
Plus Price To Sales Ratio History
About Plus Therapeutics Financial Statements
Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 1.12 | 1.06 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.